Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Pozen Resubmits PA NDA, PDUFA In Two Months?

On July 1, 2014, Pozen Inc (NASDAQ:POZN) announced it had resubmitted the New Drug Application (NDA) for PA81/40 and PA325/40 to the U.S. FDA. Pozen noted that the FDA is expected to notify the company within 14 days of receipt of the NDA whether or not the submission will be accepted, and if accepted, what the new PDUFA date will be. More specifically, we will find out in two weeks if the FDA will take two months or six months to review the application.

We remind investors that on April 25, 2014, Pozen announced receipt of a complete response letter (NYSE:CRL) for PA8140/PA32540. In the CRL, the FDA noted that, "During an inspection of the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details